Procedural advice on paediatric applications
Procedural advice on paediatric applications
Procedural advice on paediatric applications
Human medicines European public assessment report (EPAR): Prometax, rivastigmine, Date of authorisation: 04/12/1998, Revision: 50, Status: Authorised
Nitrosamines Safety Operational Expert Group
PSUSA/00000464/202407
Agenda of the CAT meeting 14-16 April 2025
European Medicines Agency (EMA) Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) Working Parties joint meeting, European Medicines Agency, Amsterdam, the Netherlands, from 1 April 2025, 09:00 (CEST) to 2 April 2025, 15:50 (CEST)
Minimum inhibitory concentration (MIC) breakpoints
Evaluation of medicinal products indicated for treatment of bacterial infections - Scientific guideline
Opinion/decision on a Paediatric investigation plan (PIP): Tenkasi (previously Orbactiv), oritavancin (diphosphate), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0074/2024
Opinion/decision on a Paediatric investigation plan (PIP): Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron), Dinutuximab beta, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0076/2024